AFM
ECYT

Anson Funds Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Anson Funds Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-191,300
Closed -$270K – 79
2017
Q3 		$270K Hold
191,300
– – 0.04% 51
2017
Q2 		$287K Buy
+191,300
New +$411K 0.09% 39
2017
Q1 		– Sell
-108,426
Closed -$276K – 97
2016
Q4 		$276K Buy
+108,426
New +$311K 0.09% 62

Other funds holding ECYT

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Anson Funds Management's ECYT Position: Q4 2017 in Review

Anson Funds Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 191,300 shares — an estimated $270K sold.

Anson Funds Management first reported a position in ECYT in Q4 2016 and held it in 3 quarters. The position peaked at $287K in Q2 2017. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

  • Anson Funds Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Anson Funds Management sold 191,300 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $270K.
  • Anson Funds Management first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 3 quarters.
  • Anson Funds Management's Endocyte, Inc. Common Stock position peaked at $287K in Q2 2017.
  • 71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on Anson Funds Management's 13F filing for Q4 2017, filed 14 Feb 2018.